Log in

NASDAQ:GHDXGenomic Health Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$63.44
0.00 (0.00 %)
(As of 11/8/2019)
Add
Compare
Today's Range
$63.44
Now: $63.44
$63.44
50-Day Range
$63.44
MA: $64.79
$69.79
52-Week Range
$50.77
Now: $63.44
$90.18
VolumeN/A
Average Volume1.05 million shs
Market Capitalization$2.38 billion
P/E Ratio60.42
Dividend YieldN/A
Beta0.9
Genomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. It offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. The company also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy; Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk prostate cancer, as well as to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score; and Oncotype DX AR-V7 nucleus detect tests for men with metastatic castration-resistant prostate cancer. In addition, it develops Oncoytpe DXi IVD breast recurrence score test; and Oncotype DX GPS test. The company offers its products through a network of distributors. Genomic Health, Inc. has license and development agreement with Biocartis N.V. to develop and commercialize an in vitro diagnostic of the Oncotype DX breast cancer test; collaboration agreement with Epic Sciences, Inc. to commercializeAR-V7 Nucleus Detect test; and license and development agreement with Cleveland Diagnostics, Inc. to develop and commercialize new prostate cancer tests. The company was founded in 2000 and is based in Redwood City, California.
Read More
Genomic Health logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.19 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GHDX
CUSIP37244C10
Phone650-556-9300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$394.11 million
Cash Flow$1.45 per share
Book Value$7.48 per share

Profitability

Net Income$25.68 million

Miscellaneous

Employees829
Market Cap$2.38 billion
Next Earnings DateN/A
OptionableOptionable

Receive GHDX News and Ratings via Email

Sign-up to receive the latest news and ratings for GHDX and its competitors with MarketBeat's FREE daily newsletter.

Genomic Health (NASDAQ:GHDX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Genomic Health?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genomic Health in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Genomic Health.

How were Genomic Health's earnings last quarter?

Genomic Health, Inc. (NASDAQ:GHDX) released its earnings results on Monday, November, 11th. The medical research company reported $0.48 earnings per share for the quarter, beating analysts' consensus estimates of $0.37 by $0.11. Genomic Health had a net margin of 12.81% and a return on equity of 19.62%. View Genomic Health's earnings history.

What price target have analysts set for GHDX?

5 Wall Street analysts have issued 12-month target prices for Genomic Health's shares. Their forecasts range from $72.00 to $72.00. On average, they expect Genomic Health's stock price to reach $72.00 in the next twelve months. This suggests a possible upside of 13.5% from the stock's current price. View analysts' price targets for Genomic Health.

What are Wall Street analysts saying about Genomic Health stock?

Here are some recent quotes from research analysts about Genomic Health stock:
  • 1. According to Zacks Investment Research, "Over the past year, Genomic Health has been outperforming its industry. The company is registering robust top-line growth banking on solid performance in the United States and internationally. In the last-reported quarter, breast cancer revenues were strong driven by increased Oncotype DX Breast Recurrence Score test usage globally which is amplifying on favorable results from the landmark TAILORx trial. Within the prostate cancer space, the company is seeing robust improvement in volume as the Oncotype DX GPS test consistently leads the market in low- and intermediate-risk prostate cancer test adoption. However, the company’s sole reliance on the Breast Oncotype DX test is a concern. Moreover, the company continues to face fierce competition for Oncotype DX tests." (7/31/2019)
  • 2. Canaccord Genuity analysts commented, "We are also lowering our price target from $77 to the deal price of $72. Our prior $77 PT used a 6.7x multiple on our 2021 revenue estimate of $540M. We note that our peer group (as of today) is trading at 6.7x our 2020 revenue estimates." (7/30/2019)

Has Genomic Health been receiving favorable news coverage?

News stories about GHDX stock have been trending negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Genomic Health earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Genomic Health.

Who are some of Genomic Health's key competitors?

What other stocks do shareholders of Genomic Health own?

Who are Genomic Health's key executives?

Genomic Health's management team includes the following people:
  • Ms. Kimberly J. Popovits, Chairman, CEO & Pres (Age 60)
  • Dr. Steven Shak, Co-Founder & Chief Scientific Officer (Age 68)
  • Mr. G. Bradley Cole, Chief Financial Officer (Age 63)
  • Dr. Frederic G. Pla, Chief Operating Officer (Age 60)
  • Mr. James J. Vaughn, Chief U.S. Commercial Officer (Age 56)

What is Genomic Health's stock symbol?

Genomic Health trades on the NASDAQ under the ticker symbol "GHDX."

What is Genomic Health's stock price today?

One share of GHDX stock can currently be purchased for approximately $63.44.

How big of a company is Genomic Health?

Genomic Health has a market capitalization of $2.38 billion and generates $394.11 million in revenue each year. The medical research company earns $25.68 million in net income (profit) each year or $1.05 on an earnings per share basis. Genomic Health employs 829 workers across the globe.

What is Genomic Health's official website?

The official website for Genomic Health is www.genomichealth.com.

How can I contact Genomic Health?

Genomic Health's mailing address is 301 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The medical research company can be reached via phone at 650-556-9300 or via email at [email protected]

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.